BRILIQUE® (ticagrelor)

BRILIQUE (ticagrelor) is the only P2Y12 inhibitor licensed in combination with aspirin to protect patients with prior MI and a high risk* of atherothrombotic events against subsequent CV events in both the acute and long-term treatment settings†1

*High risk is defined as ≥1 additional atherothrombotic risk factor (age ≥65 years, >1 prior MI, multivessel coronary artery disease, diabetes requiring medication, chronic non-end-stage renal dysfunction)1

BRILIQUE (ticagrelor) 90mg twice daily  in combination with  acetylsalicylic acid (ASA) is indicated for patients with Acute Coronary Syndromes (ACS) for up to 12 months. BRILIQUE (ticagrelor) 90mg twice daily is not indicated for use in patients beyond 12 months. There are limited data on the efficacy and safety of BRILIQUE (ticagrelor) 60mg beyond 3 years of extended treatment

Resources

These resources can be used to support you and your patients or to help support you when making prescribing decisions:

Why are patients still at risk after their heart attack?

Understanding the atherothrombotic risk

Brilique (ticagrelor) patient leaflet

A helpful guide to Brilique (ticagrelor) for patients, plus answers to questions patients might have

Heart attack secondary prevention poster

Core components of secondary prevention in post-acute myocardial infarction patients